TLDR:
- De Rubertis predicts a new wave of biotech IPOs to arrive in the summer.
- Increased activity in secondary stock offerings indicates a healthy market for investors.
In a recent interview at the LSX World Conference in London, Francesco De Rubertis, co-founder and partner of Medicxi, expressed his belief that the next wave of biotech IPOs will make their debut in the summer. While the initial surge in public offerings had slowed down by the spring, De Rubertis noted that the current lull is a normal cycle in the market. He cited the growing popularity of secondary stock offerings among publicly-listed biotechs as an indicator of investor excitement and market health.
Medicxi, with its latest $400 million fund launched in July 2023, has been approached by bankers looking to facilitate more biotech IPOs. Despite the mixed fortunes of the first wave of biotechs that went public this year, De Rubertis remains optimistic. He dismissed recent stock price fluctuations among these companies as part of the natural market cycle.
It will be interesting to see how De Rubertis’ predictions unfold as the summer approaches, and whether the expected wave of biotech IPOs will indeed materialize.
